Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1656 - Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours


10 Oct 2016


Poster display


Jordi Rodon


Annals of Oncology (2016) 27 (6): 114-135. 10.1093/annonc/mdw368


J. Rodon1, K. Peltola2, A. Azaro1, E. Castanon Alvarez3, C. Garratt4, H. Leskinen5, H. Bjorklund6, A. Ruck4, C. Massard3, P. Bono2

Author affiliations

  • 1 Medical Oncology, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
  • 2 Comprehensive Cancer Center, HUCH Helsinki University Central Hospital, 00029 - Helsinki/FI
  • 3 Drug Development Department (ditep), Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4 Oncology And Critical Care, Orion Pharma, NG1 1AH - Nottingham/GB
  • 5 Drug Safety, Orion Pharma, Helsinki/FI
  • 6 Drug Metabolism, Orion Pharma, Turku/FI


Abstract 1656


Inhibitors of fibroblast growth factor receptors (FGFR) are being developed for treatment of solid tumours with FGFR genetic alterations. ODM-203 is a small molecule with balanced inhibitory effects on both FGFR 1-4 and VEGFR 1-3 subtypes. We present updated results from the first-in-man study.


ODM-203 was evaluated in an open 3 + 3 dose escalation design to identify the maximum tolerated dose (MTD), dosed daily in a 4 week cycle. Subsequent cohorts are evaluating the optimal dose and alternative dosing schedules. Pharmacokinetics and safety variables were closely monitored during the first 4 weeks with tumour response according to RECIST recorded every 8 weeks on treatment. Patients continued ODM-203 treatment until disease progression or dose limiting toxicity (DLT).


31 patients (median age 54, range 28-80 years) with advanced solid tumours received ODM-203 treatment in doses between 50-800mg once/day during the dose escalation phase. Patients had various primary tumours, some having FGFR alterations. One cholangiocarcinoma patient with FGFR2 fusion has been treated for more than 1 year. One DLT (corneal keratopathy) was recorded at 800mg/day but MTD was not identified. A single grade 4 AE (lipase increase) was reported. Most AE's reported were grade 1-2, the most common ones being increased bilirubin (61%), diarrhoea (36%), alopecia (29%), jaundice (26%), increased phosphate (26%), stomatitis (23%) and epistaxis (19%). Increased bilirubin was due to UGT1A1 inhibition by ODM-203 and resolved in all cases upon dose reduction/interruption. Plasma ODM-203 exposure was variable. There were 3 partial responses (RCC, ovarian and FGFR mutated salivary gland cancer) and 5 further patients achieved target lesion reduction. In addition, 4 patients had disease stabilisation of at least 24wk. Further follow-up and results of ongoing dose schedule evaluation will also be presented.


In ODM-203 treated patients there was preliminary evidence of promising anti-tumour activity although FGFR-aberrant tumours were not preselected. ODM-203 elicited on-target adverse effects in addition to bilirubin changes. An expansion study in patients with FGFR-aberrant or VEGFR sensitive tumours is ongoing.

Clinical trial identification


Legal entity responsible for the study

Orion Corporation, Orion Pharma


Orion Corporation, Orion Pharma


J. Rodón: Consulting/Advisory role: Novartis, Lilly/ImClone, Servier. K. Peltola: Employment: Orion Corporation. Stock: Faron Pharmaceuticals. Consulting/honoraria: Lilly, Sanofi, Novartis, Baxalter, Bristol Myers Squibb, Pfizer. C. Garratt, H. Leskinen, H. Bjorklund, A. Ruck: Employee of Orion Pharma. P. Bono: Honoraria: MSD, Orion Pharma, Novartis, Bristol Myers Squibb, Pfizer. Research funding: Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings